Why keeping a Wegovy journal changes how you experience treatment

What the STEP 1 trial tells us about staying engaged with treatment

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks on semaglutide 2.4mg alongside lifestyle intervention. Average body-weight reduction was around 15%. That figure often gets quoted in isolation, but the trial also showed that the weight lost accumulated steadily across the full period, it was not front-loaded in the first month. People who understood their own trajectory, and who stayed in dialogue with their care team, were better placed to push through the slower middle weeks when progress feels invisible.

A written record helps with exactly that. When you note your weekly weight each Monday, or whenever injection day falls, you build a personal chart that often reveals a slow-and-steady trend even when the scales feel stuck, and our guide to the semaglutide journey week by week can help you understand what that trend is likely to look like at each stage. It also makes it much easier to spot if something genuine has changed, rather than mistaking a normal plateau for the treatment failing. Our clinical team at nume reviews these conversations every time someone comes back for a repeat, the more clearly you can describe what has been happening, the better that review goes.

Think of it like a running record rather than a formal diary. A note in your phone, a scrap of paper on the fridge, or a simple spreadsheet all work equally well. Consistency matters more than format.

The symptoms worth logging, and why they cluster around dose-step dates

The most common side effects of Wegovy are gastrointestinal: nausea, loose stools, bloating, indigestion, and occasionally vomiting. For most people they are mild and settle within a fortnight of starting or stepping up. But they feel worse when they arrive unexpectedly, and they are easy to misattribute, food poisoning? A bug? The treatment?

Dating your symptoms against your dose-step dates removes most of the guesswork. If nausea starts on day two of the new dose and fades by day ten, that is a predictable, documented pattern. If it starts six weeks in with no dose change and lasts more than a few days, that is a different conversation. The NHS medicines page for semaglutide describes what to expect and which symptoms should prompt you to seek advice urgently, it is worth reading that page once and keeping the key signals in mind as you write your journal entries.

One symptom worth logging carefully is any stomach pain that is severe or radiates to your back. That warrants prompt medical attention. Noting the date, the severity, and whether eating made it worse takes thirty seconds and could make a meaningful difference to how quickly you are assessed.

You can also record things that improve: energy levels, hunger between meals, how you feel about food generally. Many people are surprised to find these positives emerge weeks before the scales move in a way they notice.

What to track beyond the weekly weigh-in

Weight is the headline, but it is not the whole story. A useful journal also captures injection day and time (consistency matters for weekly medicines), the injection site you used, any local reactions, and how much you ate or drank in the hours before and after the injection. Hydration is particularly worth noting in the early weeks, because GI side effects combined with reduced appetite can lead to not drinking enough, something a prescriber can advise on directly if you flag it.

If you are taking oral contraceptives, your journal is a useful place to note that too. NHS guidance is clear that women taking the pill alongside tirzepatide need to use an additional method during specific windows, and semaglutide users are advised to discuss contraception with their prescriber. The detail matters, and having the dates written down makes the conversation easier.

If you are thinking about the financial side of treatment, it is worth reading our Wegovy price guide alongside the evidence on what sustained treatment actually delivers, the two conversations belong together. Some people find it helpful to note in their journal when their next supply arrives, particularly if it spans a bank holiday or a payday. A gap in supply can disrupt momentum in ways that are worth flagging early rather than scrambling at the last minute.

For the fuller picture of what semaglutide treatment looks like month by month, if you are curious about what Wegovy was originally developed to treat that background can help make sense of why it works the way it does at each stage, so you can calibrate your own experience against it.

Sharing your journal with your prescriber at review

At nume, every repeat order goes through a fresh clinical review, a real prescriber reads your notes, not a checklist algorithm. That review is more productive when the person on the other side of it has a record to refer to. You do not need to write essays. A sentence or two per week, covering weight, any symptoms, and anything that felt different, is enough.

If you have been tracking and something stands out (a plateau lasting more than six weeks, symptoms that have not settled, a dose step that felt harder than the last) those are exactly the things to raise. The prescriber's role is to look at the whole picture: your progress, your tolerance, and whether your current dose is the right one, and our guide to starting on Wegovy 1 explains what that early phase typically involves. A well-kept journal makes that assessment sharper.

You can find out more about what Wegovy treatment involves, and how the process works, on our Wegovy overview page or read about the broader weight-loss treatment options we support. When you are ready to speak to our team, starting a free consultation is the first step, our prescribers are there to help you work out whether Wegovy is the right fit and, as part of your Wegovy journey, to support you properly once treatment begins.